8-K filing — Dermata Therapeutics, Inc. (DRMA)
Filed: 2026-11-17 AccNo: 0001493152-26-052715 Size: 199 KB Item 8.01: Other Events
Stocks · News reference
Dermata Therapeutics released additional clinical study results and before-and-after photography for its Tome Foundational Treatment, a recently launched skin renewal product.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-17 AccNo: 0001493152-26-052715 Size: 199 KB Item 8.01: Other Events
Dermata Therapeutics announced its financial results for the third quarter of 2026, highlighting its transition to a revenue-generating commercial skincare business following the launch of Tome Foundational Treatment.
Dermata Therapeutics announced that its Tome skincare brand has received editorial coverage in several prominent beauty and lifestyle publications following its August 2026 commercial launch.
Dermata Therapeutics has enrolled the first participant in a clinical trial for its Tome Clearing Treatment, an acne product expected to launch in the first half of 2027.
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.